Hualan Biological Vaccine Inc. (SHE:301207)
17.22
-0.48 (-2.71%)
Sep 11, 2026, 3:04 PM CST
Hualan Biological Vaccine Revenue
Hualan Biological Vaccine had revenue of 17.61M CNY in the quarter ending June 30, 2026, a decrease of -50.64%. This brings the company's revenue in the last twelve months to 1.19B, up 3.01% year-over-year. In the year 2025, Hualan Biological Vaccine had annual revenue of 1.20B with 6.62% growth.
Revenue (ttm)
1.19B
Revenue Growth
+3.01%
P/S Ratio
8.63
Revenue / Employee
1.68M
Employees
708
Market Cap
10.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20B | 74.69M | 6.62% |
| Dec 31, 2024 | 1.13B | -1.28B | -53.21% |
| Dec 31, 2023 | 2.41B | 584.79M | 32.03% |
| Jan 1, 2023 | 1.83B | -4.17M | -0.23% |
| Jan 1, 2022 | 1.83B | -596.52M | -24.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Nanjing Vazyme Biotech | 1.47B |
| Shanghai Medicilon | 1.38B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Sino Biological,Inc. | 768.00M |